The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bendapar     methyl N-(6-propylsulfanyl-1H...

Synonyms: Disthelm, Endoplus, Eskazole, Metiazol, Valbazen, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Eskazole

  • CONCLUSIONS: Percutaneous drainage, combined with albendazole therapy, is an effective and safe alternative to surgery for the treatment of uncomplicated hydatid cysts of the liver and requires a shorter hospital stay [1].
  • All patients received 15 mg of albendazole per kilogram of body weight per day for four weeks [2].
  • We aimed to assess the potential for school-based control of lymphatic filariasis by investigating the efficacy and tolerability or combined ivermectin and albendazole in Haitian schoolchildren [3].
  • INTERPRETATION: Symptomless trichuriasis impairs growth and albendazole or pyrantel may affect growth, independently of a therapeutic action on parasites [4].
  • Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study [5].

Psychiatry related information on Eskazole

  • We conclude that treatment of undernourished school children for intestinal helminth infections with albendazole may improve growth and appetite and increase spontaneous physical activity [6].
  • Both albendazole-treated groups had significant side effects (anorexia, lethargy) [7].
  • It is concluded that co-infection with M. perstans does not significantly alter the post-treatment reaction profile to single-dose ivermectin/albendazole in W. bancrofti infection in this community, and that acute post-treatment reactions should not limit patient compliance in community-based programs to eliminate lymphatic filariasis [8].

High impact information on Eskazole


Chemical compound and disease context of Eskazole


Biological context of Eskazole


Anatomical context of Eskazole


Associations of Eskazole with other chemical compounds


Gene context of Eskazole

  • The aim of this work was to determine whether albendazole, a CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein [30].
  • Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes [31].
  • Both in vitro and in vivo methods were used to assess the role of P-glycoprotein-mediated albendazole transport [30].
  • CONCLUSIONS: These findings suggest for the first time that in nude mice bearing OVCAR-3 peritoneal tumors, by inhibiting VEGF production, albendazole abolishes tumor angiogenesis and ascites formation [19].
  • Postvaccination levels of IL-2 were significantly greater in the albendazole-treated group compared with the placebo group (P = 0.03) [32].

Analytical, diagnostic and therapeutic context of Eskazole


  1. Percutaneous drainage compared with surgery for hepatic hydatid cysts. Khuroo, M.S., Wani, N.A., Javid, G., Khan, B.A., Yattoo, G.N., Shah, A.H., Jeelani, S.G. N. Engl. J. Med. (1997) [Pubmed]
  2. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. Proaño, J.V., Madrazo, I., Avelar, F., López-Félix, B., Díaz, G., Grijalva, I. N. Engl. J. Med. (2001) [Pubmed]
  3. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Addiss, D.G., Beach, M.J., Streit, T.G., Lutwick, S., LeConte, F.H., Lafontant, J.G., Hightower, A.W., Lammie, P.J. Lancet (1997) [Pubmed]
  4. Randomised trial of albendazole and pyrantel in symptomless trichuriasis in children. Forrester, J.E., Bailar, J.C., Esrey, S.A., José, M.V., Castillejos, B.T., Ocampo, G. Lancet (1998) [Pubmed]
  5. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Khuroo, M.S., Dar, M.Y., Yattoo, G.N., Zargar, S.A., Javaid, G., Khan, B.A., Boda, M.I. Gastroenterology (1993) [Pubmed]
  6. Physical activity and growth of Kenyan school children with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved after treatment with albendazole. Adams, E.J., Stephenson, L.S., Latham, M.C., Kinoti, S.N. J. Nutr. (1994) [Pubmed]
  7. Treatment of porcine cysticercosis with albendazole. Gonzalez, A.E., Garcia, H.H., Gilman, R.H., Lopez, M.T., Gavidia, C., McDonald, J., Pilcher, J.B., Tsang, V.C. Am. J. Trop. Med. Hyg. (1995) [Pubmed]
  8. Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans. Keiser, P.B., Coulibaly, Y.I., Keita, F., Traore, D., Diallo, A., Diallo, D.A., Semnani, R.T., Doumbo, O.K., Traore, S.F., Klion, A.D., Nutman, T.B. Am. J. Trop. Med. Hyg. (2003) [Pubmed]
  9. Treatment of anisakiasis with albendazole. Moore, D.A., Girdwood, R.W., Chiodini, P.L. Lancet (2002) [Pubmed]
  10. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Gil-Grande, L.A., Rodriguez-Caabeiro, F., Prieto, J.G., Sánchez-Ruano, J.J., Brasa, C., Aguilar, L., García-Hoz, F., Casado, N., Bárcena, R., Alvarez, A.I. Lancet (1993) [Pubmed]
  11. Sensitivity to albendazole sulphoxide of Echinococcus granulosus scoleces in man. Morris, D.L., Taylor, D. Lancet (1986) [Pubmed]
  12. Albendazole as a potential treatment for human hydatidosis. Saimot, A.G., Meulemans, A., Cremieux, A.C., Giovanangeli, M.D., Hay, J.M., Delaitre, B., Coulaud, J.P. Lancet (1983) [Pubmed]
  13. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Bennett, A., Guyatt, H. Parasitol. Today (Regul. Ed.) (2000) [Pubmed]
  14. Penetration of albendazole sulphoxide into hydatid cysts. Morris, D.L., Chinnery, J.B., Georgiou, G., Stamatakis, G., Golematis, B. Gut (1987) [Pubmed]
  15. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. Dionisio, D., Sterrantino, G., Meli, M., Leoncini, F., Orsi, A., Nicoletti, P. AIDS (1996) [Pubmed]
  16. Human cysticercosis: parasitology, pathology, clinical manifestations and available treatment. Webbe, G. Pharmacol. Ther. (1994) [Pubmed]
  17. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Didier, E.S. Antimicrob. Agents Chemother. (1997) [Pubmed]
  18. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Steiger, U., Cotting, J., Reichen, J. Clin. Pharmacol. Ther. (1990) [Pubmed]
  19. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Pourgholami, M.H., Yan Cai, Z., Lu, Y., Wang, L., Morris, D.L. Clin. Cancer Res. (2006) [Pubmed]
  20. Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Rigter, I.M., Schipper, H.G., Koopmans, R.P., van Kan, H.J., Frijlink, H.W., Kager, P.A., Guchelaar, H.J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  21. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. Cooper, P.J., Chico, M.E., Losonsky, G., Sandoval, C., Espinel, I., Sridhara, R., Aguilar, M., Guevara, A., Guderian, R.H., Levine, M.M., Griffin, G.E., Nutman, T.B. J. Infect. Dis. (2000) [Pubmed]
  22. Anthelmintics. A comparative review of their clinical pharmacology. de Silva, N., Guyatt, H., Bundy, D. Drugs (1997) [Pubmed]
  23. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. Klion, A.D., Massougbodji, A., Horton, J., Ekoué, S., Lanmasso, T., Ahouissou, N.L., Nutman, T.B. J. Infect. Dis. (1993) [Pubmed]
  24. Unintentional percutaneous aspiration of a pleural hydatid cyst. al Karawi, M.A., Mohamed, A.R., el Tayeb, B.O., Yasawy, M.I. Thorax (1991) [Pubmed]
  25. Polymerase chain reaction and culture confirmation of disseminated Encephalitozoon cuniculi in a patient with AIDS: successful therapy with albendazole. De Groote, M.A., Visvesvara, G., Wilson, M.L., Pieniazek, N.J., Slemenda, S.B., daSilva, A.J., Leitch, G.J., Bryan, R.T., Reves, R. J. Infect. Dis. (1995) [Pubmed]
  26. Microsporidial AIDS cholangiopathy due to Encephalitozoon intestinalis: case report and review. Sheikh, R.A., Prindiville, T.P., Yenamandra, S., Munn, R.J., Ruebner, B.H. Am. J. Gastroenterol. (2000) [Pubmed]
  27. Comparison of albendazole, mebendazole and praziquantel chemotherapy of Echinococcus multilocularis in a gerbil model. Taylor, D.H., Morris, D.L., Reffin, D., Richards, K.S. Gut (1989) [Pubmed]
  28. Drug treatment of tropical parasitic infections: recent achievements and developments. Stephenson, I., Wiselka, M. Drugs (2000) [Pubmed]
  29. Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes. Ingold, K., Bigler, P., Thormann, W., Cavaliero, T., Gottstein, B., Hemphill, A. Antimicrob. Agents Chemother. (1999) [Pubmed]
  30. The anthelminthic agent albendazole does not interact with p-glycoprotein. Merino, G., Alvarez, A.I., Prieto, J.G., Kim, R.B. Drug Metab. Dispos. (2002) [Pubmed]
  31. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Rawden, H.C., Kokwaro, G.O., Ward, S.A., Edwards, G. British journal of clinical pharmacology. (2000) [Pubmed]
  32. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Cooper, P.J., Chico, M., Sandoval, C., Espinel, I., Guevara, A., Levine, M.M., Griffin, G.E., Nutman, T.B. Infect. Immun. (2001) [Pubmed]
  33. Alveolar echinococcosis of the liver: percutaneous stent therapy in Budd-Chiari syndrome. Vogel, J., Görich, J., Kramme, E., Merkle, E., Sokiranski, R., Kern, P., Brambs, H.J. Gut (1996) [Pubmed]
  34. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. Blanshard, C., Ellis, D.S., Tovey, D.G., Dowell, S., Gazzard, B.G. AIDS (1992) [Pubmed]
  35. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Del Brutto, O.H. Neurology (1994) [Pubmed]
  36. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Takayanagui, O.M., Jardim, E. Arch. Neurol. (1992) [Pubmed]
WikiGenes - Universities